Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Killed but metabolically active vaccines.

Dubensky TW Jr, Skoble J, Lauer P, Brockstedt DG.

Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18. Review.

PMID:
22608846
2.

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.

Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr.

Nat Med. 2005 Aug;11(8):853-60. Epub 2005 Jul 24.

PMID:
16041382
3.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.

4.

Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.

Singh R, Wallecha A.

Hum Vaccin. 2011 May;7(5):497-505. Epub 2011 May 1. Review.

PMID:
21422819
5.

Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector.

Lankowski AJ, Hohmann EL.

J Infect Dis. 2007 Apr 15;195(8):1203-11. Epub 2007 Mar 5.

PMID:
17357059
6.

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.

Zuckermann FA, Martin S, Husmann RJ, Brandt J.

Adv Vet Med. 1999;41:447-61. Review.

PMID:
9890035
7.

Vaccines against leishmaniasis.

Modabber F.

Ann Trop Med Parasitol. 1995 Dec;89 Suppl 1:83-8. Review.

PMID:
8745930
8.

Live-attenuated Listeria-based immunotherapy.

Rothman J, Paterson Y.

Expert Rev Vaccines. 2013 May;12(5):493-504. doi: 10.1586/erv.13.34. Review.

PMID:
23659298
9.

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.

Brockstedt DG, Dubensky TW.

Expert Rev Vaccines. 2008 Sep;7(7):1069-84. doi: 10.1586/14760584.7.7.1069. Review.

PMID:
18767955
10.
11.

[Development of a killed but metabolically active anthracis vaccine candidate strain].

Shen F, Yuan S, Zhan D, Wang Y, Ren M, Tao H, Wang P, Wang L, Chen D, Liu C.

Sheng Wu Gong Cheng Xue Bao. 2011 May;27(5):781-9. Chinese.

PMID:
21845845
12.

Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease.

Weiskirch LM, Paterson Y.

Immunol Rev. 1997 Aug;158:159-69. Review.

PMID:
9314084
13.

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V.

Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi: 10.1128/CVI.00274-08. Epub 2008 Nov 19.

14.

[New technologies for vaccine development].

Leclerc C.

Med Sci (Paris). 2007 Apr;23(4):386-90. Review. French.

15.

Cancer vaccines: an update with special focus on ganglioside antigens.

Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.

Oncol Rep. 2002 Mar-Apr;9(2):267-76. Review.

PMID:
11836591
16.

Progress on vaccines against parasites.

Engers HD, Bergquist R, Modabber F.

Dev Biol Stand. 1996;87:73-84. Review.

PMID:
8854004
17.

Recent advances in vaccines for leishmaniasis.

Requena JM, Iborra S, Carrión J, Alonso C, Soto M.

Expert Opin Biol Ther. 2004 Sep;4(9):1505-17. Review.

PMID:
15335317
18.

[Listeria monocytogenes: a dangerous pathogen used as a vector for the new generation of vaccines].

Tkachuk MV, Iarovinskiĭ FO, Tonevitskiĭ AG.

Vopr Med Khim. 2000 May-Jun;46(3):256-64. Review. Russian.

PMID:
11033885
19.

New approaches in vaccine development.

Leclerc C.

Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):329-41. Review.

PMID:
12818620
20.

Vaccines for bluetongue.

Murray PK, Eaton BT.

Aust Vet J. 1996 Jun;73(6):207-10. Review.

PMID:
8893989

Supplemental Content

Support Center